Itopride,
ApprovedSmall molecule
Itopride, is one of 82 small molecule programs targeting Dyspepsia. It is currently in Approved.
3
Indications
19
Total Trials
2
Active Trials
81
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
99 competitors in Dyspepsia
#DrugCompanyPhaseTrials
1Lexapro
AbbViePhase 3
Tofranil
SanofiPhase 3
Elavil
AstraZenecaPhase 3
Neurontin
VViatris Specialty LLC
Phase 3
Pamelor
SSpecgx
Phase 3
Domperidone
Johnson & JohnsonPhase 3
Itopride,
FForest Laboratories
Approved
Xifaxan
SSalix
Phase 2
Nereus
VVanda Pharmaceuticals
Phase 2
Aciphex
Akero TherapeuticsPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Dyspepsia8 trials
Effect Of Itopride On Gastric Emptying And Accommodation In Patients With Functional Dyspepsia
Unknown status·—·N/A·NCT01226134·30 enrolled
Show 5 more trials
Randomized Controlled Trial of Acupuncture for Functional Dyspepsia
Completed·—·N/A·NCT00599677·720 enrolled
Function2 trials
Fatty Liver Disease1 trial
Age1 trial
Comparing Acotiamide and Itopride for the Management of Indigestion
Not yet recruiting·—·Phase 4·NCT07449689·368 enrolled
6 more indications
Peritonitis1 trial
Functional Gastrointestinal Disorders1 trial
Effectiveness1 trial
Feeding Intolerance1 trial
Itopride in Feeding Intolerance of Critically-ill Patients Receiving Enteral Nutrition
Unknown status·—·N/A·NCT03698292·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Itopride,. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- FForest Laboratories